Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACULAR LS vs AMIKACIN SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
FDA: Treatment of postoperative inflammation in patients who have undergone cataract surgery,Off-label: Relief of ocular pain, photophobia, and inflammation associated with corneal abrasion or refractive surgery
FDA-approved: Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus) when other antibiotics are ineffective or contraindicated.,Off-label: Used in combination for enterococcal endocarditis, mycobacterial infections (e.g., tuberculosis), and severe neonatal sepsis.
1 drop in the affected eye(s) four times daily
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
The terminal elimination half-life is approximately 1.8 hours (range 1.2–2.5 hours) following topical ocular administration. This short half-life is consistent with rapid clearance from the systemic circulation.
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
Primarily hepatic via CYP2C9; undergoes glucuronidation and oxidation to inactive metabolites.
Amikacin is not significantly metabolized; it is excreted unchanged primarily by glomerular filtration. Minimal hepatic metabolism.
Renal excretion of metabolites and unchanged drug accounts for approximately 26% of the dose. Fecal excretion accounts for approximately 74% of the dose, primarily as metabolites.
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
Ketorolac is highly protein bound, approximately 99% bound to plasma proteins, primarily albumin.
0-11% (low binding to albumin).
The volume of distribution is approximately 0.12 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
0.25-0.4 L/kg; approximates extracellular fluid volume; increased in edema, decreased in dehydration.
Ophthalmic bioavailability is approximately 2% of the administered dose due to extensive nasolacrimal drainage and systemic absorption. Oral bioavailability of ketorolac is approximately 80-100%, but this route is not used for ophthalmic formulations.
IM: nearly 100% (rapid and complete).
No dosage adjustment required for renal impairment
Cr Cl 20-50 m L/min: 7.5 mg/kg every 24 hours; Cr Cl 10-20 m L/min: 7.5 mg/kg every 48 hours; Cr Cl <10 m L/min: 7.5 mg/kg every 72-96 hours; hemodialysis: 7.5 mg/kg post-dialysis with monitoring.
No dosage adjustment required for hepatic impairment but use with caution in severe hepatic disease due to potential for increased systemic exposure
No dose adjustment required for hepatic impairment; monitor drug levels if severe dysfunction.
Safety and efficacy in pediatric patients below 2 years of age have not been established; for children 2 years and older, same as adult dosing
Neonates <7 days: 15-20 mg/kg IV every 24-48 hours; neonates 7-28 days: 15 mg/kg every 24 hours; infants/children: 15-22.5 mg/kg/day divided every 8-12 hours; maximum 1.5 g/day.
No specific dose adjustment recommended; use with caution due to increased incidence of age-related ocular conditions
Reduce initial dose based on renal function; usual dose 7.5 mg/kg every 24-48 hours with close monitoring of serum creatinine and drug levels due to age-related decreased GFR.
None
WARNING: Amikacin can cause neurotoxicity, ototoxicity, and nephrotoxicity. The risk of nephrotoxicity is greater in patients with impaired renal function and those receiving high doses or prolonged therapy. Ototoxicity may be irreversible and can occur even after drug discontinuation. Monitor renal function and drug levels closely.
Increased risk of bleeding and bleeding-related adverse events due to platelet inhibition,May prolong bleeding time,Cross-sensitivity with aspirin and other NSAIDs,Caution in patients with prior history of corneal epithelial defects or ocular surgery,Not for intraocular injection
Nephrotoxicity: Risk increased with advanced age, pre-existing renal impairment, concomitant use of other nephrotoxic drugs (e.g., amphotericin B, cyclosporine, NSAIDs).,Ototoxicity: Can cause irreversible bilateral hearing loss, tinnitus, and vestibular damage. Monitor audiometry in patients with risk factors.,Neuromuscular blockade: May exacerbate weakness in patients with neuromuscular disorders (e.g., myasthenia gravis, Parkinsonism). Use with caution during anesthesia or with neuromuscular blocking agents.,Hypersensitivity reactions: Including rash, drug fever, and anaphylaxis.,Superinfection: Prolonged use may lead to overgrowth of nonsusceptible organisms.,Pregnancy: Risk of fetal harm (ototoxicity) if administered during pregnancy.
Hypersensitivity to ketorolac tromethamine or any component of the formulation,Patients with active peptic ulcer disease, recent GI bleeding, or perforation,Patients with advanced renal disease or at risk for renal failure,Patients with known history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
Hypersensitivity to amikacin, other aminoglycosides, or any component of the formulation.,Preexisting severe renal impairment (unless life-threatening infection and no alternative).,Concurrent use of other nephrotoxic or ototoxic drugs (relative contraindication).,Myasthenia gravis (caution; neuromuscular blocking effect).
No known food interactions for ophthalmic ketorolac. However, maintain good hydration and nutrition to support corneal healing.
No significant food interactions. Avoid alcohol as it may increase side effects like dizziness.
Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during organogenesis resulted in increased embryofetal mortality, delayed ossification, and increased incidence of skeletal abnormalities at doses less than the maximum recommended human ophthalmic dose. However, systemic exposure following ocular administration is very low. NSAIDs are generally avoided during pregnancy, especially in the third trimester, due to the risk of premature closure of the ductus arteriosus and oligohydramnios. The risk is considered low for ophthalmic use but should be used only if clearly needed.
Aminoglycosides including amikacin have been associated with fetal ototoxicity and nephrotoxicity when administered during pregnancy. There is a potential for eighth cranial nerve damage and renal impairment in the fetus, particularly during the second and third trimesters. Animal studies have shown evidence of harm, but controlled human studies are lacking. Use only if clearly needed and if safer alternatives are unavailable.
It is not known whether ketorolac is excreted in human milk after ophthalmic administration. Systemic levels are low, and following oral administration, ketorolac is excreted in breast milk at low concentrations (M/P ratio approximately 0.37). Due to the potential for adverse effects on the nursing infant, caution should be exercised. The low systemic absorption likely poses minimal risk.
Amikacin is excreted into human milk in low concentrations. The milk-to-plasma ratio is approximately 0.1–0.2. Due to low oral bioavailability from the gastrointestinal tract, systemic effects in the breastfed infant are unlikely. However, caution is advised due to the potential for altered infant gut flora and direct mucosal irritation. Use only if benefits outweigh risks.
No dosing adjustments are necessary for ophthalmic use during pregnancy due to negligible systemic absorption. Standard dosing (1 drop in the affected eye(s) four times daily) is recommended. Systemic NSAIDs may require dose adjustment due to increased volume of distribution and renal changes, but this does not apply to topical ocular ketorolac.
Pregnancy does not typically require dosing adjustments for amikacin. However, due to increased glomerular filtration rate during pregnancy, levels may be lower; monitor drug concentrations and adjust doses to achieve therapeutic range. Standard dosing based on ideal body weight and renal function should be followed.
ACULAR LS (ketorolac tromethamine ophthalmic solution 0.4%) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the reduction of ocular pain and photophobia following corneal refractive surgery. Use with caution in patients with known bleeding tendencies or those on anticoagulants due to increased risk of ocular bleeding. Avoid concurrent use with other NSAIDs or steroids to minimize corneal adverse effects. Monitor for corneal epithelial breakdown or delayed healing.
Monitor peak (15-30 mcg/m L) and trough (<5 mcg/m L) levels to avoid nephrotoxicity and ototoxicity. Adjust dose in renal impairment using Cr Cl. Synergy with beta-lactams for Gram-negative infections. Avoid concurrent loop diuretics.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 10 minutes before reinserting.,Use only in the affected eye(s) as prescribed; do not use for longer than directed.,Temporary stinging or burning may occur upon instillation.,Report any persistent pain, redness, or visual changes to your doctor immediately.,Avoid driving or operating machinery if vision is blurred after use.
Take exactly as prescribed; do not skip doses or stop early.,Report any hearing loss, tinnitus, dizziness, or vertigo immediately.,Drink plenty of fluids to maintain hydration, unless contraindicated.,Avoid taking other medications without consulting your doctor, especially water pills or other antibiotics.
No interactions on record
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACULAR LS vs AMIKACIN SULFATE, answered by our medical review team.
ACULAR LS is a NSAID Ophthalmic that works by Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.. AMIKACIN SULFATE is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACULAR LS and AMIKACIN SULFATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACULAR LS is: 1 drop in the affected eye(s) four times daily. The standard adult dose of AMIKACIN SULFATE is: 15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACULAR LS and AMIKACIN SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACULAR LS is classified as Category C. Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during org. AMIKACIN SULFATE is classified as Category D/X. Aminoglycosides including amikacin have been associated with fetal ototoxicity and nephrotoxicity when administered during pregnancy. There is a potential for eighth cranial nerve . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.